title: Haematological malignancies: at the forefront of immunotherapeutic innovation.
abstract: The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.
authors: 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors: Pavan
authors: P
authors: Bachireddy
authors: Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
authors: Ute E
authors: UE
authors: Burkhardt
authors: 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Bristol-Meyers Squibb, Princeton, New Jersey 08540, USA.
authors: Mohini
authors: M
authors: Rajasagi
authors: 1] Department of Medical Oncology and the Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. [2] Broad Institute, Cambridge, Massachusetts 02142, USA. [3] Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors: Catherine J
authors: CJ
authors: Wu
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy
chemical_list: D019496:Cancer Vaccines